➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Harvard Business School
Express Scripts
Johnson and Johnson
Colorcon

Last Updated: September 24, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FLUOXETINE HYDROCHLORIDE; OLANZAPINE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Fluoxetine Hydrochloride; Olanzapine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed National Institute of Mental Health (NIMH) Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00000373 ↗ Treatment of Obsessive-Compulsive Disorder Completed University of Florida Phase 4 1992-09-01 The purpose of this study is to find the best treatment for Tourette's Syndrome (TS)-spectrum obsessive-compulsive disorder (OCD), which includes symptoms of TS, e.g., repeated and involuntary body movements (tics). There are 2 parts to this study: In Part 1, patients are placed into 1 of 2 groups based on type of OCD, determined by medical history and family member interviews. In Part 2, patients are treated with fluvoxamine (FVX) for 8 weeks. If patients do not respond to FVX alone, either haloperidol or an inactive placebo will be added to the FVX regimen; patients will take this drug combination for 4 weeks. Patients will be monitored throughout the trial.
NCT00035321 ↗ The Study of Olanzapine Plus Fluoxetine in Combination for Treatment of Treatment Resistant Depression Completed Eli Lilly and Company Phase 3 2002-04-01 The purposes of this study are to determine: - Whether olanzapine plus fluoxetine in combination will help patients with treatment-resistant major depression. - The safety of olanzapine plus fluoxetine in combination, plus and any side effects that might be associated with the combination. - The effectiveness of olanzapine plus fluoxetine compared to olanzapine and fluoxetine alone.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Fluoxetine Hydrochloride; Olanzapine

Condition Name

Condition Name for Fluoxetine Hydrochloride; Olanzapine
Intervention Trials
Bipolar Depression 3
Major Depressive Disorder 3
Treatment Resistant Depression 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Fluoxetine Hydrochloride; Olanzapine
Intervention Trials
Depression 11
Depressive Disorder 10
Bipolar Disorder 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Fluoxetine Hydrochloride; Olanzapine

Trials by Country

Trials by Country for Fluoxetine Hydrochloride; Olanzapine
Location Trials
United States 45
Canada 5
Puerto Rico 2
India 2
Russian Federation 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Fluoxetine Hydrochloride; Olanzapine
Location Trials
Pennsylvania 3
California 3
Massachusetts 2
New York 2
Florida 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Fluoxetine Hydrochloride; Olanzapine

Clinical Trial Phase

Clinical Trial Phase for Fluoxetine Hydrochloride; Olanzapine
Clinical Trial Phase Trials
Phase 4 8
Phase 3 3
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Fluoxetine Hydrochloride; Olanzapine
Clinical Trial Phase Trials
Completed 10
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Fluoxetine Hydrochloride; Olanzapine

Sponsor Name

Sponsor Name for Fluoxetine Hydrochloride; Olanzapine
Sponsor Trials
Eli Lilly and Company 7
GlaxoSmithKline 1
National Alliance on Mental Illness 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Fluoxetine Hydrochloride; Olanzapine
Sponsor Trials
Other 13
Industry 8
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Merck
Colorcon
McKinsey
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.